It has been suggested that FBXO16 might serve as a clinical target for therapeutic intervention, particularly in breast cancer, where its role as a prognostic biomarker across distinct molecular subtypes is being explored [60]. The gene discussed is FBXO16; the disease is breast carcinoma.